Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Akshanth R PolepallySven MensingAmit KhatriDenise BeckWei LiuWalid M AwniRajeev M MenonSandeep DuttaPublished in: Clinical pharmacokinetics (2017)
The complex pharmacokinetics of paritaprevir were well described by the model, which can be used as a basis for clinical trial dosing and further evaluations in patients with HCV.